Pay in 4 interest-free payments of $6.83 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
A post hoc analysis of the phase IIb trial showed that tirzepatide was associated with a reduction in the level of high-sensitivity ICAM-1, CRP, and YKL-40 after 26 weeks of treatment in a dose-dependent manner [83, 103]
Decreased appetite is also very common and may contribute to the weight reduction observed in some patients
The study authors cited GLP-1-related weight loss and changes in nutritional status as risk factors for telogen effluvium, a type of non-scarring alopecia
It has only been a month but Im very happy so far
Timing, dosing, and administration decisions should be made in consultation with a qualified research supervisor or licensed prescribing physician where applicable
Where are the knowledge gaps, and what still needs investigation
